Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | CCR8 | P51685 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.58 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.58 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.58 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028218 | 1.00 | CHRM4 (0.64) | CHRM4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL6178711 | 0.87 | CCR8 (0.54) | CHRM4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL1266245 | 0.86 | CCR3 (0.59) | CHRM4OPRL1CCR8POLBSIGMAR1 | |
| SCHEMBL6924615 | 0.85 | OPRL1 (0.57) | CHRM4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL1513216 | 0.85 | OPRL1 (0.60) | CHRM4OPRL1CCR8POLBSIGMAR1 | |
| SCHEMBL7490166 | 0.85 | OPRL1 (0.60) | CHRM4OPRL1CCR8POLBSIGMAR1 | |
| SCHEMBL6924622 | 0.84 | OPRL1 (0.56) | CHRM4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL8959892 | 0.84 | CHRM4 (0.52) | CHRM4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL6911078 | 0.82 | OPRL1 (0.71) | OPRL1POLBSIGMAR1CCR3MEN1 | |
| SCHEMBL2883677 | 0.81 | OPRL1 (0.66) | OPRL1OPRM1OPRD1OPRK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024168037-A2 | COMPOUNDS FOR TREATING OPIOID MISUSE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-15 | — | — | WO | disclosed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| CN-100345833-C | Modulators of dopamine neurotransmission | CARLSSON RES AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| CN-1256326-C | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| CN-1255382-C | Novel modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2006-05-10 | — | — | CN | disclosed |
| CN-1765890-A | Modulators of dopamine neurotransmission | CARLSSON RES AB (SE) | 2006-05-03 | — | — | CN | disclosed |
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | SSP CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6124316-A | ACTIVE DRUG TREATING PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, OF HYPERTENSION AND, NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 2000-09-26 | — | — | US | disclosed |
| US-5942523-A | NOVEL PIPERIDINE DERIVATIVES WHOSE SPECIFIC STRUCTURE INCLUDES AT POSITION 1 AN ALKYL CHAIN HAVING A 3,4-DICHLOROPHENYL GROUP ATTACHED; HIGH SELECTIVITY TO THE NK3 RECEPTOR; UNIT DOSAGE FORM; TREATING PSYCHIATRIC DISEASES | SANOFI (FR) | 1999-08-24 | — | — | US | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| US-5741910-A | PIPERIDINE DERIVATIVE INTERMEDIATES | SANOFI (FR) | 1998-04-21 | — | — | US | disclosed |
| EP-0372776-B1 | Arylpiperidine derivatives | PFIZER (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | disclosed |
| US-5294619-A | N-(nitrogen-containing heterocyclylalkyl-phenyl-piperidines | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5153206-A | Neuroleptic agents for treating psychological disorders | PFIZER INC. (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1990006303-A1 | ARYLPIPERIDINE DERIVATIVES | PFIZER INC. (US) | 1990-06-14 | — | — | WO | disclosed |
| EP-0372776-A2 | Arylpiperidine derivatives | PFIZER INC. (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | CHRM4 4797/4885OPRL1 4622/4885OPRM1 4589/4885 |
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | OPRD1, OPRM1, OPRK1 | CHRM4 1162/4885OPRL1 4/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.